Comparing two antibiotic combinations for drug-resistant infections
Part of Infections clinical trials.
This study tests which of two antibiotic combinations works better at clearing infections caused by multi-drug-resistant bacteria in adults, including those with weakened immune systems. It aims to find a more effective treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old
- You have a confirmed bacterial infection that is resistant to multiple antibiotics
- You may be immunocompromised (have a weakened immune system)
- You have not had an allergic reaction to the study antibiotics
- You are not pregnant or breastfeeding
- You have not had recent seizures or other serious brain or nervous system events
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different antibiotic combinations (ampicillin/sulbactam and cefoperazone/sulbactam) to see which works better against a type of bacteria (Acinetobacter baumannii) that is resistant to many other drugs. It is for critically ill patients with signs of sepsis.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This study looks at two strong antibiotics, polymyxin B and colistin, given through a vein to treat serious infections like pneumonia or blood infections caused by bacteria that are resistant to many other antibiotics. The goal is to see how well they work and how safe they are.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
This trial aims to improve how antibiotics are chosen for patients with resistant bacterial infections in the blood. It uses faster diagnostic tests and expert advice to ensure the most effective treatment.
Hear when a new MDR Bacteria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.